Dear Sir, Mark and DeFronzo [1] reviewed 'Glucose and insulin metabolism in uremia' in Nephron , recently. The review of the distinguished contributors presents a clearcut evidence on the mechanism and significance of this alteration. However, one of the mentioned points is to be extended: insulin resistance and glucose intolerance (IR/GI) in uremia, besides common mechanisms with other diseases share a specific feature, i. e., the effect of accumulated end products excreted or eliminated otherwise insufficiently by the kidney. At least 2 end products were defined sufficiently, i.e., hippurate [2] and pseudou-ridine [3] which accumulate in uremia because of insufficient urinary excretion. Hippurate inhibits glucose utilization in isolated rat diaphragm (table 1) at concentrations found in uremia, with maximal inhibitory activity 86,6%. Moreover, it inhibits also insulinstimulated glucose utilization if insulin is administered to rats in vivo 30 min before sacrifice to assure its binding and even partial internalization [4]. Pseudouridine inhibits glucose utilization in isolated rat soleus muscle (intact superficial membrane) also at concentrations found in uremia [5]. It inhibits insulin-stimulated glucose utilization both in the case of insulin addition to incubation medium or administered to rat in vivo. Pseudouridine inhibits also tolbutamide-stimulated glucose utilization by 30%. However, tolbutamide stimulates glucose utilization independently from insulin receptor by closing the ATP-depend-ent K+ channel and by opening a voltage-operated Ca channel and increasing Ca concentration intracellularly. As intracellular Ca concentration is also a link of insulin regulatory cascade, it could be hypothetized that modulation of intracellular free Ca concentration in muscle is the site of the inhibition of IR/GI caused by these accumulated end products. In accordance with these results is also the inhibition of glucose utilization by diltia-zem and the additive effect of pseudouridine (table 1) . The finding of the hippurate and pseudouridine insulin postreceptor effect is in accordance with the insulin postreceptor inhibition of glucose utilization in patients [6] and the localization of inhibition at the intracellular Ca with the potential significance of PTH and hormones of vitamin D [1]. The accumulated hippurate, pseudouridine and eventually other inhibitors could participate in the late development of IR/GI in most patients with kidney diseases in contrast to early development of IR/GI in other diseases such as hypertension or obesity. 
Dear Sir, Mark and DeFronzo [1] reviewed 'Glucose and insulin metabolism in uremia' in Nephron , recently. The review of the distinguished contributors presents a clearcut evidence on the mechanism and significance of this alteration. However, one of the mentioned points is to be extended: insulin resistance and glucose intolerance (IR/GI) in uremia, besides common mechanisms with other diseases share a specific feature, i. e., the effect of accumulated end products excreted or eliminated otherwise insufficiently by the kidney. At least 2 end products were defined sufficiently, i.e., hippurate [2] and pseudou-ridine [3] which accumulate in uremia because of insufficient urinary excretion. Hippurate inhibits glucose utilization in isolated rat diaphragm (table 1) at concentrations found in uremia, with maximal inhibitory activity 86,6%. Moreover, it inhibits also insulinstimulated glucose utilization if insulin is administered to rats in vivo 30 min before sacrifice to assure its binding and even partial internalization [4] . Pseudouridine inhibits glucose utilization in isolated rat soleus muscle (intact superficial membrane) also at concentrations found in uremia [5] . It inhibits insulin-stimulated glucose utilization both in the case of insulin addition to incubation medium or administered to rat in vivo. Pseudouridine inhibits also tolbutamide-stimulated glucose utilization by 30%. However, tolbutamide stimulates glucose utilization independently from insulin receptor by closing the ATP-depend-ent K+ channel and by opening a voltage-operated Ca channel and increasing Ca concentration intracellularly. As intracellular Ca concentration is also a link of insulin regulatory cascade, it could be hypothetized that modulation of intracellular free Ca concentration in muscle is the site of the inhibition of IR/GI caused by these accumulated end products. In accordance with these results is also the inhibition of glucose utilization by diltia-zem and the additive effect of pseudouridine (table 1) . The finding of the hippurate and pseudouridine insulin postreceptor effect is in accordance with the insulin postreceptor inhibition of glucose utilization in patients [6] and the localization of inhibition at the intracellular Ca with the potential significance of PTH and hormones of vitamin D [1]. The accumulated hippurate, pseudouridine and eventually other inhibitors could participate in the late development of IR/GI in most patients with kidney diseases in contrast to early development of IR/GI in other diseases such as hypertension or obesity. 
